Join our daily newsletter At The Bell to receive exclusive market insights
- Recce Pharmaceuticals (RCE) receives a notification of intent to grant an Australian patent for synthetic anti-infectives
- The grant from the Australian Patent Office relates to the RECCE 327 (R327) and RECCE 529 (R529) formulations, marking the final patent of “Family three”
- This patent follows those already granted in the biggest pharmaceutical markets in the world, and will expire in November 2037
- Recce’s CEO James Graham says receiving this notice is another milestone in the company’s global IP strategy
- Shares in Recce are up 4.62 per cent, trading at 68 cents as of 12:40 pm AEDT
Recce Pharmaceuticals (RCE) has been issued a notification of intent to grant Recce’s Patent family Three.
The patent, entitled “Anti-Virus Agent and Method for Treatment of Viral Infection” relates to its RECCE 327 (R327) and anti-viral formulation RECCE 529 (R529).
The patent most notably claims the composition and method of manufacture of RECCE anti-infectives, the use of either for the treatment of viruses having a lipid envelope or
coat and administering by oral, injection, inhalation and transdermal dose applications.
This marks the final patent of “Family 3”, following those already granted in the biggest pharmaceutical markets in the world such as China, Europe and Hong Kong.
CEO James Graham said receiving the notice to grant is another milestone in the company’s global IP strategy and is further validation to the potential importance of
our infectious disease compounds.
Like the other patents in the “Family 3”, the Australian patent will expire in November 2037.
Shares in Recce were up 4.62 per cent, trading at 68 cents as of 12:40 pm AEDT.
